Charles Bisgaier - Gemphire Therapeutics Insider

GEMP -- USA Stock  

USD 1.65  0.24  17.02%

Dr. Charles L. Bisgaier Ph.D., is Chairman of the Board, Chief Scientific Officer of the Company
Age: 62  Founder Since 2014  Ph.D    
Bisgaier was an Associate Research Fellow in the Department of Vascular and Cardiac Disease at WarnerLambert/ParkeDavis. There he participated in the discovery and/or development of gemfibrozil, atorvastatin and gemcabene . Subsequently, Dr. Bisgaier cofounded the first Esperion Therapeutics, which was then acquired by Pfizer. At Pfizer he then served as the Senior Director of Pharmacology at the Esperion Division of Pfizer Global Research and Development. Notably, he was a major influence in the discovery, research and/or development of many small molecules with potential utility for metabolic syndrome including ETC1002 which was licensed by the new Esperion from Pfizer, as well as HDLtherapy product candidates, such as ApoAI Milano which was also licensed by The Medicines Company from Pfizer

Charles Bisgaier Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (62.2) % which means that it has lost $62.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (143.74) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 10.12 M in liabilities with Debt to Equity (D/E) ratio of 48.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gemphire Therapeutics has Current Ratio of 5.46 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Gemphire Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of dyslipidemia and non-alcoholic steatohepatitis . The company was founded in 2008 and is headquartered in Livonia, Michigan. Gemphire Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 17 people.Gemphire Therapeutics (GEMP) is traded on NASDAQ General Markets in USA. It is located in 17199 North Laurel Park Drive and employs 17 people.

Gemphire Therapeutics Leadership Team

Charles Bisgaier, Co-Founder, Chief Scientific Officer
Mina Sooch, President CEO
Kenneth Kousky, Independent Director
Andrew Sassine, Independent Director
Jeffrey Mathiesen, CFO
Seth Reno, Chief Commercial Officer
Pedro Lichtinger, Independent Director
Steven Gullans, Interim President Interim CEO, Director
David Lowenschuss, Co-Founder, Chief Legal Officer
Kent Hawryluk, Independent Director
Lee Golden, Chief Medical Officer

Stock Performance Indicators

Current Sentiment - GEMP

Gemphire Therapeutics Investor Sentiment
Macroaxis portfolio users are indifferent in their judgment towards investing in Gemphire Therapeutics. What is your judgment towards investing in Gemphire Therapeutics? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.